Inventor · disambiguated record
Alan L. Epstein
Also filed as: EPSTEIN ALAN · EPSTEIN ALAN L
35 granted patents·20 pending applications·1,201 citations·filing 1985–2025
98Inventor score
Files withUNIV SOUTHERN CALIFORNIA29EPSTEIN ALAN L10CANCER THERAPEUTICS LABORATORIES INC4TECHNICLONE INC4CANCER BIOLOG INC3
Top patents by PatentIndex Score
55 records- 0197US7514073B2Therapeutic use of interleukin-2 mutantsUNIV SOUTHERN CALIFORNIA·Filed 2005·Granted Apr 7, 2009·49 cites·7 claims
- 0297US5019368ADetection of necrotic malignant tissue and associated therapyCANCER BIOLOG INC·Filed 1989·Granted May 28, 1991·174 cites·9 claims
- 0397US4861581ADetection of necrotic malignant tissue and associated therapyCANCER BIOLOG INC·Filed 1986·Granted Aug 29, 1989·194 cites·8 claims
- 0496US8124066B2Methods of using interleukin-2 mutants with reduced toxicityEPSTEIN ALAN L·Filed 2010·Granted Feb 28, 2012·37 cites·12 claims
- 0595US7803361B2Therapeutic use of interleukin-2 mutantsUNIV SOUTHERN CALIFORNIA·Filed 2009·Granted Sep 28, 2010·31 cites·8 claims
- 0695US7696175B2Combination cancer immunotherapy with co-stimulatory moleculesUNIV SOUTHERN CALIFORNIA·Filed 2005·Granted Apr 13, 2010·78 cites·55 claims
- 0795US7371371B2Interleukin-2 mutants with reduced toxicityUNIV SOUTHERN CALIFORNIA·Filed 2002·Granted May 13, 2008·59 cites·11 claims
- 0894US9522958B2Cancer targeted innate immunityEPSTEIN ALAN L·Filed 2011·Granted Dec 20, 2016·34 cites·12 claims
- 0994US5194594AModified antibodiesTECHNICLONE INC·Filed 1990·Granted Mar 16, 1993·181 cites·13 claims
- 1090US6017514ADetection of necrotic malignant tissue and associated therapyTECHNICLONE INC·Filed 1999·Granted Jan 25, 2000·71 cites·9 claims
- 1189US12258421B2Humanized anti-nuclear antibodies for targeting necrosis in cancer therapyCANCER THERAPEUTICS LABORATORIES INC·Filed 2022·Granted Mar 25, 2025·1 cites·17 claims
- 1286US8268788B2Combination cancer immunotherapy with co-stimulatory moleculesEPSTEIN ALAN·Filed 2010·Granted Sep 18, 2012·6 cites·60 claims
- 1386US5990286AAntibodies with reduced net positive chargeTECHNICLONE INC·Filed 1997·Granted Nov 23, 1999·79 cites·11 claims
- 1484US4724213AMurine hybridoma Lym-1 and diagnostic antibody produced therebyUNIV NORTHWESTERN·Filed 1985·Granted Feb 9, 1988·47 cites·2 claims
- 1584US2024392011A1Hla-g as a novel target for car t-cell immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2024·Application pending·0 cites
- 1684US2025129171A1Car t-cell therapy directed to lhr for the treatment of solid tumorsUNIV SOUTHERN CALIFORNIA·Filed 2024·Application pending·0 cites
- 1782US8207130B2Combination cancer immunotherapy with co-stimulatory moleculesEPSTEIN ALAN·Filed 2010·Granted Jun 26, 2012·3 cites·22 claims
- 1881US11384157B2Humanized anti-nuclear antibodies for targeting necrosis in cancer therapyCANCER THERAPEUTICS LABORATORIES INC·Filed 2018·Granted Jul 12, 2022·1 cites·20 claims
- 1981US8545838B2Compositions and methods for cancer immunotherapyEPSTEIN ALAN L·Filed 2007·Granted Oct 1, 2013·3 cites·46 claims
- 2079US5882626ADetection of necrotic malignant tissue and associated therapyCANCER BIOLOG INC·Filed 1991·Granted Mar 16, 1999·35 cites·8 claims
- 2178US10711064B2Lym-1 and Lym-2 targeted CAR cell immunotherapyEPSTEIN ALAN L·Filed 2016·Granted Jul 14, 2020·1 cites·16 claims
- 2278US10196435B2OX40L fusion protein for the immunotherapy of tumors of veterinary animalsEPSTEIN ALAN L·Filed 2014·Granted Feb 5, 2019·2 cites·8 claims
- 2377US6071491ADetection of necrotic malignant tissue and associated therapyTECHNICLONE INC·Filed 1999·Granted Jun 6, 2000·33 cites·6 claims
- 2476US11136401B2Car t-cell therapy directed to LHR for the treatment of solid tumorsUNIV SOUTHERN CALIFORNIA·Filed 2016·Granted Oct 5, 2021·1 cites·16 claims
- 2574US8883497B2Human myeloid derived suppressor cell cancer markersEPSTEIN ALAN L·Filed 2012·Granted Nov 11, 2014·4 cites·8 claims
- 2673US8795672B2Compositions and methods for cancer immunotherapyEPSTEIN ALAN L·Filed 2004·Granted Aug 5, 2014·2 cites·7 claims
- 2772US6008319AVasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereofUNIV SOUTHERN CALIFORNIA·Filed 1996·Granted Dec 28, 1999·29 cites·23 claims
- 2872US4724212AMurine hybridoma Lym-2 and diagnostic antibody produced therebyUNIV NORTHWESTERN·Filed 1985·Granted Feb 9, 1988·22 cites·2 claims
- 2972US2021403585A1Car t-cell therapy directed to lhr for the treatment of solid tumorsUNIV SOUTHERN CALIFORNIA·Filed 2021·Application pending·0 cites
- 3072US2024150470A1Lym-1 and lym-2 antibody compositions and improved car constructsUNIV SOUTHERN CALIFORNIA·Filed 2023·Application pending·0 cites
- 3171US11667715B2Lym-1 and Lym-2 antibody compositions and improved car constructsUNIV SOUTHERN CALIFORNIA·Filed 2021·Granted Jun 6, 2023·0 cites·30 claims
- 3268US2021070864A1Hla-g as a novel target for car t-cell immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2020·Application pending·0 cites
- 3366US6524823B2Vasopermeability-enhancing conjugatesUNIV SOUTHERN CALIFORNIA·Filed 2001·Granted Feb 25, 2003·2 cites·20 claims
- 3466US2021147551A1Lym-1 and lym-2 targeted car cell immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2020·Application pending·0 cites
- 3565US2025215114A1Humanized anti-nuclear antibodies for targeting necrosis in cancer therapyCANCER THERAPEUTICS LABORATORIES INC·Filed 2025·Application pending·0 cites
- 3663US6007817AVasopermeability enhancing immunoconjugatesUNIV SOUTHERN CALIFORNIA·Filed 1995·Granted Dec 28, 1999·19 cites·56 claims
- 3762US2014099305A1Compositions and methods for cancer immunotherapyEPSTEIN ALAN L·Filed 2013·Application pending·0 cites
- 3860US10961317B2CD20 scFv-ELPs methods and therapeuticsUNIV SOUTHERN CALIFORNIA·Filed 2019·Granted Mar 30, 2021·0 cites·22 claims
- 3960US6737064B2Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2UNIV SOUTHERN CALIFORNIA·Filed 2002·Granted May 18, 2004·0 cites·2 claims
- 4060US6696276B2Vasopermeability-enhancing conjugatesUNIV SOUTHERN CALIFORNIA·Filed 2003·Granted Feb 24, 2004·0 cites·18 claims
- 4159US2019119385A1Hla-g as a novel target for car t-cell immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2016·Application pending·0 cites
- 4257US2005201979A1Interleukin-2 mutants with reduced toxicityUNIV SOUTHERN CALIFORNIA·Filed 2005·Application pending·0 cites
- 4357US2023331849A1CpG IMMUNOCONJUGATES FOR CANCER THERAPYUNIV SOUTHERN CALIFORNIA·Filed 2021·Application pending·0 cites
- 4453US9746480B2Human myeloid derived suppressor cell cancer markersEPSTEIN ALAN L·Filed 2014·Granted Aug 29, 2017·0 cites·3 claims
- 4553US2004156824A1Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereofFiled 2004·Application pending·0 cites
- 4651US2006135459A1Targeted innate immunityEPSTEIN ALAN L·Filed 2005·Application pending·0 cites
- 4750US2005214286A1Polymer-bound antibody cancer therapeutic agentUNIV SOUTHERN CALIFORNIA·Filed 2005·Application pending·0 cites
- 4849US2015218280A1CD20 scFv-ELPs METHODS AND THERAPEUTICSUNIV SOUTHERN CALIFORNIA·Filed 2013·Application pending·0 cites
- 4942US2020016201A1Chimeric antigen receptors and compositions and methods of use thereofUNIV SOUTHERN CALIFORNIA·Filed 2017·Application pending·0 cites
- 5042US2020147230A1Tumor necrosis targeting compositions and methodsCANCER THERAPEUTICS LABORATORIES INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →